中世纪托尼
Lv6
1780 积分
2023-11-29 加入
-
MA15.13 Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations
1个月前
已关闭
-
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
1个月前
已完结
-
Surgery after Preoperative Chemotherapy for Patients with Unresectable Advanced Gastric Cancer
1个月前
已关闭
-
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
-
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
3个月前
已完结
-
The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer
3个月前
已关闭
-
Study on the effect of protein lysine lactylation modification in macrophages on inhibiting periodontitis in rats
5个月前
已完结
-
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
-
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
-
Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors
5个月前
已完结